$AVTX
Avalo Therapeutics, Inc. Stock $avtx

$avtx Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-K Financial Statement

#000162828019003078 Filed on March 18, 2019

Income Statement

Concept	2019 Q1	2018	2017 Q4
Revenue	$2.600M	$7.028M	$1.911M
YoY Change	-42.0%	-74.73%	950.0%
Cost Of Revenue	$752.5K	$3.261M	$636.0K
YoY Change	-12.86%	412.97%
Gross Profit	$1.847M	$3.768M	$1.275M
YoY Change	-48.95%	-86.14%
Gross Profit Margin	71.06%	53.61%	66.72%
Selling, General & Admin	$3.072M	$11.06M	$3.994M
YoY Change	-30.87%	29.9%	266.42%
% of Gross Profit	166.28%	293.45%	313.25%
Research & Development	$3.401M	$5.787M	$1.961M
YoY Change	106.16%	32.34%	153.69%
% of Gross Profit	184.1%	153.58%	153.8%
Depreciation & Amortization	$1.098M	$4.555M	$410.0K
YoY Change	7.37%	970.56%	4000.0%
% of Gross Profit	59.46%	120.89%	32.16%
Operating Expenses	$12.43M	$57.64M	$5.955M
YoY Change	50.95%	313.99%	670.38%
Operating Profit	-$5.005M	-$35.38M	-$4.680M
YoY Change	33.3%	-354.71%
Interest Expense	$30.22K	$16.26K	$31.00K
YoY Change	-130.1%	-167.71%	-137.35%
% of Operating Profit
Other Income/Expense, Net	-$26.76K	$54.93K
YoY Change	-74.51%	-202.4%
Pretax Income	-$5.032M	-$35.32M	-$4.360M
YoY Change	30.35%	-355.3%	165.85%
Income Tax	$130.7K	-$49.47K	-$3.460M
% Of Pretax Income
Net Earnings	-$7.454M	-$40.05M	-$3.091M
YoY Change	91.97%	-437.43%	88.59%
Net Earnings / Revenue	-286.69%	-569.87%	-161.75%
Basic Earnings Per Share		-$1.20	-$0.11
Diluted Earnings Per Share	-$2.16	-$1.20	-$0.11
COMMON SHARES
Basic Shares Outstanding	42.65M shares	34.77M shares	26.05M shares
Diluted Shares Outstanding		34.77M shares

Balance Sheet

Concept	2019 Q1	2018	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.12M	$10.65M	$2.470M
YoY Change	539.68%	330.64%	-51.85%
Cash & Equivalents	$16.12M	$10.65M	$2.472M
Short-Term Investments		$0.00
Other Short-Term Assets	$1.330M	$4.883M	$700.0K
YoY Change	70.51%	592.46%	75.0%
Inventory	$1.047M	$317.9K	$382.2K
Prepaid Expenses
Receivables	$2.720M	$822.3K	$2.940M
Other Receivables	$5.530M	$5.262M	$4.170M
Total Short-Term Assets	$26.74M	$21.93M	$10.67M
YoY Change	99.69%	105.47%	88.5%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.477M	$586.5K	$44.61K
YoY Change	2437.7%	1214.75%	3.17%
Goodwill	$16.41M		$12.29M
YoY Change	-12.14%
Intangibles	$30.16M		$17.66M
YoY Change	-8.88%
Long-Term Investments
YoY Change
Other Assets	$80.00K	$29.56M	$130.0K
YoY Change	-38.46%	22403.21%	116.67%
Total Long-Term Assets	$48.13M	$48.32M	$32.13M
YoY Change	-7.39%	50.37%	30193.6%
TOTAL ASSETS
Total Short-Term Assets	$26.74M	$21.93M	$10.67M
Total Long-Term Assets	$48.13M	$48.32M	$32.13M
Total Assets	$74.87M	$70.25M	$42.81M
YoY Change	14.55%	64.11%	642.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.249M	$1.446M	$1.299M
YoY Change	-60.53%	11.33%	28.59%
Accrued Expenses	$11.01M	$5.374M	$7.530M
YoY Change	57.74%	-20.83%	701.06%
Deferred Revenue			$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.050M		$0.00
YoY Change	33.33%		-100.0%
Total Short-Term Liabilities	$28.13M	$26.22M	$11.09M
YoY Change	90.25%	136.41%	157.18%
LONG-TERM LIABILITIES
Long-Term Debt	$14.30M	$0.00	$0.00
YoY Change	-1.97%
Other Long-Term Liabilities	$1.189M	$23.06M	$24.27K
YoY Change	290.91%	498.75%
Total Long-Term Liabilities	$15.49M	$23.06M	$24.27K
YoY Change	4.02%	498.75%
TOTAL LIABILITIES
Total Short-Term Liabilities	$28.13M	$26.22M	$11.09M
Total Long-Term Liabilities	$15.49M	$23.06M	$24.27K
Total Liabilities	$51.75M	$49.34M	$14.95M
YoY Change	26.91%	230.11%	168.75%
SHAREHOLDERS EQUITY
Retained Earnings	-$105.7M		-$58.17M
YoY Change	70.48%		-16.95%
Common Stock	$42.75K		$31.27K
YoY Change	36.11%		231.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$23.12M	$20.91M	$27.86M
YoY Change
Total Liabilities & Shareholders Equity	$74.87M	$70.25M	$42.81M
YoY Change	14.55%	64.11%	642.03%

Cashflow Statement

Concept	2019 Q1	2018	2017 Q4
OPERATING ACTIVITIES
Net Income	-$7.454M	-$40.05M	-$3.091M
YoY Change	91.97%	-437.43%	88.59%
Depreciation, Depletion And Amortization	$1.098M	$4.555M	$410.0K
YoY Change	7.37%	970.56%	4000.0%
Cash From Operating Activities	-$3.122M	-$3.128M	-$2.550M
YoY Change	1013.16%	-124.87%	-31.27%
INVESTING ACTIVITIES
Capital Expenditures	$166.0K	$564.4K	$10.00K
YoY Change	763.34%	2319.79%
Acquisitions	$0.00	$1.00
YoY Change	-100.0%	-100.0%
Other Investing Activities	$0.00	$1.430M	-$18.89M
YoY Change		-107.57%
Cash From Investing Activities	-$166.0K	$865.5K	-$18.90M
YoY Change	763.3%	-104.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$8.976M	$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net	$24.34K	$0.00
YoY Change		-100.0%
Cash From Financing Activities	$8.817M	$10.40M	10.00K
YoY Change	2326.35%	178.4%	-66.67%
NET CHANGE
Cash From Operating Activities	-$3.122M	-$3.128M	-2.550M
Cash From Investing Activities	-$166.0K	$865.5K	-18.90M
Cash From Financing Activities	$8.817M	$10.40M	10.00K
Net Change In Cash	$5.530M	$8.141M	-21.44M
YoY Change	8574.96%	-413.56%	482.61%
FREE CASH FLOW
Cash From Operating Activities	-$3.122M	-$3.128M	-$2.550M
Capital Expenditures	$166.0K	$564.4K	$10.00K
Free Cash Flow	-$3.288M	-$3.693M	-$2.560M
YoY Change	997.13%	-129.41%	-31.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q4	us-gaap	Other Commitment Due In Second Year OtherCommitmentDueInSecondYear	3000000	USD
CY2018Q4	us-gaap	Other Commitment Due In Third Year OtherCommitmentDueInThirdYear	0	USD
CY2018	cerc	Accounts Receivable Payment Terms AccountsReceivablePaymentTerms	P30D
CY2018Q4	cerc	Accounts Receivable Prompt Payment Discount AccountsReceivablePromptPaymentDiscount	0.02
CY2017Q4	cerc	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	1001454	USD
CY2018Q4	cerc	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	1112378	USD
CY2017Q4	cerc	Accrued Liabilities And Other Current Liabilities AccruedLiabilitiesAndOtherCurrentLiabilities	7531122	USD
CY2018Q4	cerc	Accrued Liabilities And Other Current Liabilities AccruedLiabilitiesAndOtherCurrentLiabilities	19731373	USD
CY2017Q4	cerc	Accrued Medicaid Rebates AccruedMedicaidRebates	350681	USD
CY2018Q4	cerc	Accrued Medicaid Rebates AccruedMedicaidRebates	2237269	USD
CY2017Q4	cerc	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	299480	USD
CY2018Q4	cerc	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	278132	USD
CY2017Q4	cerc	Accrued Sales Returns And Allowances AccruedSalesReturnsAndAllowances	3478349	USD
CY2018Q4	cerc	Accrued Sales Returns And Allowances AccruedSalesReturnsAndAllowances	3972510	USD
CY2017	cerc	Amortization Of Inventory Fair Value Adjustment AmortizationOfInventoryFairValueAdjustment	137900	USD
CY2018	cerc	Amortization Of Inventory Fair Value Adjustment AmortizationOfInventoryFairValueAdjustment	300573	USD
CY2018Q4	cerc	Capital Stock Shares Authorized CapitalStockSharesAuthorized	205000000	shares
CY2017	cerc	Cash Acquired From Asset Acquistion CashAcquiredFromAssetAcquistion	0	USD
CY2018	cerc	Cash Acquired From Asset Acquistion CashAcquiredFromAssetAcquistion	1429877	USD
CY2017	cerc	Class Of Warrant Or Right Distribution Adjustment ClassOfWarrantOrRightDistributionAdjustment	0	USD
CY2018	cerc	Deferred Income Taxes Naked Credit Portion Not Offset By Net Operating Losses Percent DeferredIncomeTaxesNakedCreditPortionNotOffsetByNetOperatingLossesPercent	0.20
CY2018	cerc	Deferred Income Taxes Naked Credit Portion Offset By Net Operating Losses Percent DeferredIncomeTaxesNakedCreditPortionOffsetByNetOperatingLossesPercent	0.80
CY2017Q4	cerc	Deferred Tax Assets Installment Sale DeferredTaxAssetsInstallmentSale	0	USD
CY2018Q4	cerc	Deferred Tax Assets Installment Sale DeferredTaxAssetsInstallmentSale	508291	USD
CY2017Q4	cerc	Deferred Tax Assets Net Before Valuation Allowance DeferredTaxAssetsNetBeforeValuationAllowance	4016846	USD
CY2018Q4	cerc	Deferred Tax Assets Net Before Valuation Allowance DeferredTaxAssetsNetBeforeValuationAllowance	10655898	USD
CY2017Q4	cerc	Deferred Tax Assets Tax Difference In Tangible And Intangible Assets DeferredTaxAssetsTaxDifferenceInTangibleAndIntangibleAssets	2019272	USD
CY2018Q4	cerc	Deferred Tax Assets Tax Difference In Tangible And Intangible Assets DeferredTaxAssetsTaxDifferenceInTangibleAndIntangibleAssets	2968764	USD
CY2017Q4	cerc	Deferred Tax Liabilities Tax Deferred Expense Installment Sale DeferredTaxLiabilitiesTaxDeferredExpenseInstallmentSale	358844	USD
CY2018Q4	cerc	Deferred Tax Liabilities Tax Deferred Expense Installment Sale DeferredTaxLiabilitiesTaxDeferredExpenseInstallmentSale	0	USD
CY2017	cerc	Effective Income Tax Rate Reconciliation Built In Loss Percent EffectiveIncomeTaxRateReconciliationBuiltInLossPercent	0.0152
CY2018	cerc	Effective Income Tax Rate Reconciliation Built In Loss Percent EffectiveIncomeTaxRateReconciliationBuiltInLossPercent	-0.0033
CY2017	cerc	Effective Income Tax Rate Reconciliation Net Operating Loss Adjustment Per Section382 Percent EffectiveIncomeTaxRateReconciliationNetOperatingLossAdjustmentPerSection382Percent	1.2682
CY2018	cerc	Effective Income Tax Rate Reconciliation Net Operating Loss Adjustment Per Section382 Percent EffectiveIncomeTaxRateReconciliationNetOperatingLossAdjustmentPerSection382Percent	0.0000
CY2017	cerc	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.0017
CY2018	cerc	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.0037
CY2017Q3	cerc	Escrow Period EscrowPeriod	P12M
CY2017Q3	cerc	Escrow Period EscrowPeriod	P12M
CY2017	cerc	Fair Value Adjustment Of Warrants And Investor Rights Obligation FairValueAdjustmentOfWarrantsAndInvestorRightsObligation	29624	USD
CY2018	cerc	Fair Value Adjustment Of Warrants And Investor Rights Obligation FairValueAdjustmentOfWarrantsAndInvestorRightsObligation	-25010	USD
CY2017	cerc	Fair Value Measurements Changes In Valuation Techniques Number FairValueMeasurementsChangesInValuationTechniquesNumber	0	class_of_stock
CY2018	cerc	Fair Value Measurements Changes In Valuation Techniques Number FairValueMeasurementsChangesInValuationTechniquesNumber	0	class_of_stock
CY2017Q4	cerc	Finite Lived Intangible Assets Accumulated Impairment FiniteLivedIntangibleAssetsAccumulatedImpairment	0	USD
CY2018Q4	cerc	Finite Lived Intangible Assets Accumulated Impairment FiniteLivedIntangibleAssetsAccumulatedImpairment	1861562	USD
CY2017Q4	cerc	License Obligation Noncurrent LicenseObligationNoncurrent	1250000	USD
CY2018Q4	cerc	License Obligation Noncurrent LicenseObligationNoncurrent	1250000	USD
CY2017Q4	cerc	Minimum Sales Commitments Royalties Payable And Purchase Obligations Current MinimumSalesCommitmentsRoyaltiesPayableAndPurchaseObligationsCurrent	743010	USD
CY2018Q4	cerc	Minimum Sales Commitments Royalties Payable And Purchase Obligations Current MinimumSalesCommitmentsRoyaltiesPayableAndPurchaseObligationsCurrent	9662901	USD
CY2017	cerc	Net Income Loss Available To Common Stockholders Diluted Before Reallocation NetIncomeLossAvailableToCommonStockholdersDilutedBeforeReallocation	7772084	USD
CY2018	cerc	Net Income Loss Available To Common Stockholders Diluted Before Reallocation NetIncomeLossAvailableToCommonStockholdersDilutedBeforeReallocation	-41710193	USD
CY2017	cerc	Net Income Loss Available To Common Stockholders Diluted Reallocated NetIncomeLossAvailableToCommonStockholdersDilutedReallocated	49642	USD
CY2018	cerc	Net Income Loss Available To Common Stockholders Diluted Reallocated NetIncomeLossAvailableToCommonStockholdersDilutedReallocated	0	USD
CY2017	cerc	Net Income Loss Before Taxes NetIncomeLossBeforeTaxes	13836342	USD
CY2018	cerc	Net Income Loss Before Taxes NetIncomeLossBeforeTaxes	-40086720	USD
CY2015Q4	cerc	Number Of Class Of Stock Authorized NumberOfClassOfStockAuthorized	2	class_of_stock
CY2018	cerc	Number Of Marketed Medical Devices NumberOfMarketedMedicalDevices	1	product
CY2017	cerc	Payment Of Fractional Shares Upon Conversion Of Preferred Stock To Common Stock PaymentOfFractionalSharesUponConversionOfPreferredStockToCommonStock	-4	USD
CY2018	cerc	Payment Of Fractional Shares Upon Conversion Of Preferred Stock To Common Stock PaymentOfFractionalSharesUponConversionOfPreferredStockToCommonStock	0	USD
CY2017	cerc	Payments Of Stock Issuance Costs Excluding Amounts Paid To Underwriters PaymentsOfStockIssuanceCostsExcludingAmountsPaidToUnderwriters	279247	USD
CY2018	cerc	Payments Of Stock Issuance Costs Excluding Amounts Paid To Underwriters PaymentsOfStockIssuanceCostsExcludingAmountsPaidToUnderwriters	0	USD
CY2017Q3	cerc	Potential Future Regulatory Milestone PotentialFutureRegulatoryMilestone	20000000	USD
CY2017	cerc	Proceeds From Option Or Warrant Exercises ProceedsFromOptionOrWarrantExercises	0	USD
CY2018	cerc	Proceeds From Option Or Warrant Exercises ProceedsFromOptionOrWarrantExercises	1083953	USD
CY2018	cerc	Share Based Compensation Arrangement By Share Based Payment Award Share Reserve Increase As Percent ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent	0.04
CY2017	cerc	Stock Issued During Period Value Acquisitions Contingent Shares StockIssuedDuringPeriodValueAcquisitionsContingentShares	2655464	USD
CY2017	cerc	Stock Issued During Period Value New Issues Private Placement StockIssuedDuringPeriodValueNewIssuesPrivatePlacement	4561658	USD
CY2018	cerc	Stock Issued During Period Value New Issues Private Placement StockIssuedDuringPeriodValueNewIssuesPrivatePlacement	3857106	USD
CY2018	cerc	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	1083953	USD
CY2018	cerc	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	5685038	USD
CY2018	dei	Amendment Flag AmendmentFlag	false
CY2018	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2018	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018	dei	Document Period End Date DocumentPeriodEndDate	2018-12-31
CY2018	dei	Document Type DocumentType	10-K
CY2018	dei	Entity Central Index Key EntityCentralIndexKey	0001534120
CY2019Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	42653659	shares
CY2018	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2018	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2018	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2018Q2	dei	Entity Public Float EntityPublicFloat	40821693	USD
CY2018	dei	Entity Registrant Name EntityRegistrantName	Cerecor Inc.
CY2018	dei	Entity Shell Company EntityShellCompany	false
CY2018	dei	Entity Small Business EntitySmallBusiness	true
CY2018	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2018	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1298980	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1446141	USD
CY2017Q4	us-gaap	Accounts Receivable Billed For Long Term Contracts Or Programs AccountsReceivableBilledForLongTermContractsOrPrograms	427241	USD
CY2018Q4	us-gaap	Accounts Receivable Billed For Long Term Contracts Or Programs AccountsReceivableBilledForLongTermContractsOrPrograms	5469011	USD
CY2017Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	2935025	USD
CY2018Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	3157555	USD
CY2017Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	2259148	USD
CY2018Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	2032258	USD
CY2017Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	7531122	USD
CY2018Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	19731373	USD
CY2017Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	0	USD
CY2018Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	235721	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	109647	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	132163	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	83338136	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	119082157	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1157252	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2431063	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1157252	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2431063	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	400000	USD
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	403520	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4532448	USD
CY2017Q4	us-gaap	Assets Assets	42806907	USD
CY2018Q4	us-gaap	Assets Assets	70250721	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	10674180	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	21931893	USD
CY2017	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	58366	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0	USD
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	1956807	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2576633	USD
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7093757	USD
CY2018	us-gaap	Business Combination Provisional Information Initial Accounting Incomplete Adjustment Intangibles BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles	1527998	USD
CY2017Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Long Term Debt BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt	0	USD
CY2018Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Long Term Debt BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt	15075000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2472187	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10600000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10646301	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5201897	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2605499	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10746756	USD
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2596398	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8141257	USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31266989	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40804189	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	31268	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	35490	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4375690	USD
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40804189	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31266989	shares
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	160474	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	7144	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	69238	USD
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-43355	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	40804	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-17165	USD
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-789274	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-52235	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-832629	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-16745	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	358844	USD
CY2017Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	2655464	USD
CY2018Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	0	USD
CY2018Q4	us-gaap	Contractual Obligation ContractualObligation	8522704	USD
CY2018Q4	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	0	USD
CY2018Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	4257326	USD
CY2018Q4	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	4265378	USD
CY2018Q4	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	0	USD
CY2017	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	635648	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7478262	USD
CY2017	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	489863	USD
CY2018	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	36116	USD
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	2309285	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-53281	USD
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2799148	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10816372	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	716819	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4421423	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	252095	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	271437	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	465430	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1291230	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1922736	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	4051	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	15373	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	72881	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	262260	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4023990	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10725136	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	7144	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	69238	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	0	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	160474	USD
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.2791
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0443
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.0104
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0061
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1401514	USD
CY2016Q4	us-gaap	Deposits Deposits	50000	USD
CY2017	us-gaap	Depreciation Depreciation	21956	USD
CY2018	us-gaap	Depreciation Depreciation	22515	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	425476	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4554963	USD
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.42
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.20
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.42
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.20
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.1421
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0009
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1.9103
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1537
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.1582
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.0000
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.0984
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0004
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0004
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1953065	USD
CY2017Q4	us-gaap	Escrow Deposit EscrowDeposit	3752390	USD
CY2018Q4	us-gaap	Escrow Deposit EscrowDeposit	0	USD
CY2017Q3	us-gaap	Escrow Deposit EscrowDeposit	3750000	USD
CY2017Q3	us-gaap	Escrow Deposit EscrowDeposit	3750000	USD
CY2017Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2018Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2017Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2018Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2017	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	0	USD
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-58366	USD
CY2017	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P10Y0M18D
CY2018	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P9Y4M28D
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	403520	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4935968	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	12592604	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	4315318	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	2976322	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2976322	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	4082334	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	4296568	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	18068000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	38036998	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	17664480	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	31239468	USD
CY2017	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	18068000	USD
CY2018	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	18441000	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7941584	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10676881	USD
CY2018	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	3778001	USD
CY2016Q4	us-gaap	Goodwill Goodwill	0	USD
CY2017Q4	us-gaap	Goodwill Goodwill	14292282	USD
CY2018Q4	us-gaap	Goodwill Goodwill	16411123	USD
CY2017	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	14292282	USD
CY2018	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	7792259	USD
CY2017	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	USD
CY2018Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	USD
CY2018	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	-1659160	USD
CY2017	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2018	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	1861562	USD
CY2018	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	1900000	USD
CY2018Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	200000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1966519	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-33910	USD
CY2017	us-gaap	Income Taxes Paid IncomeTaxesPaid	540000	USD
CY2018	us-gaap	Income Taxes Paid IncomeTaxesPaid	354000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	96065	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	82451	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	247195	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	222530	USD
CY2017	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	2259148	USD
CY2018	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-226890	USD
CY2017	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	3752390	USD
CY2018	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-3752390	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	24276	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	311199	USD
CY2017	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	2044548	USD
CY2018	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	385517	USD
CY2017	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	427241	USD
CY2018	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	2277255	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	177691	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	241641	USD
CY2017	us-gaap	Incremental Common Shares Attributable To Equity Unit Purchase Agreements IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements	283284	shares
CY2018	us-gaap	Incremental Common Shares Attributable To Equity Unit Purchase Agreements IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements	0	shares
CY2017	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	61510	shares
CY2018	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2016Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	0	USD
CY2017Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	17664480	USD
CY2018Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	31239468	USD
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	17664480	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	31239468	USD
CY2017	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-24016	USD
CY2018	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-811621	USD
CY2017	us-gaap	Interest Paid Net InterestPaidNet	72526	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	525000	USD
CY2017Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	560499	USD
CY2018Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1427935	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	382153	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	1110780	USD
CY2017Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	0	USD
CY2018Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	328547	USD
CY2017	us-gaap	Inventory Write Down InventoryWriteDown	178346	USD
CY2018Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	11392	USD
CY2017Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	178346	USD
CY2018	us-gaap	Inventory Write Down InventoryWriteDown	150201	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	24272	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	385517	USD
CY2017	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	5858955	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3100000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3128102	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	13657	USD
CY2017	us-gaap	Paid In Kind Interest PaidInKindInterest	20364	USD
CY2017Q4	us-gaap	Liabilities Liabilities	14947299	USD
CY2018Q4	us-gaap	Liabilities Liabilities	49342973	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	42806907	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	70250721	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11089250	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	26216579	USD
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2018Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1100000	USD
CY2018Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1050000	USD
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	14327882	USD
CY2017Q4	us-gaap	Minority Interest Ownership Percentage By Noncontrolling Owners MinorityInterestOwnershipPercentageByNoncontrollingOwners	0.10
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3737081	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10403898	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-18912257	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	865461	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	12578778	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	11869823	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-40100000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-40052810	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	7772084	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-41710193	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-41700000	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	7821726	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-41710193	USD
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-53640	USD
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-772954	USD
CY2018	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2018	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reporting_unit
CY2017	us-gaap	Operating Expenses OperatingExpenses	13923155	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	57640567	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	13889982	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-39313766	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1860455	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	0	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	178092	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	173748	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	169510	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	155815	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	1183290	USD
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	41749	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	256634	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	279397	USD
CY2018	us-gaap	Paid In Kind Interest PaidInKindInterest	302882	USD
CY2017	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	USD
CY2018	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	294435	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	23325	USD
CY2018Q4	us-gaap	Other Commitment OtherCommitment	6000000	USD
CY2018Q4	us-gaap	Other Commitment Due In Fourth Year OtherCommitmentDueInFourthYear	0	USD
CY2018Q4	us-gaap	Other Commitment Due In Next Twelve Months OtherCommitmentDueInNextTwelveMonths	3000000	USD
CY2017	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	27813137	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18326801	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	154259	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	718675	USD
CY2017	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	569825	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	564415	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2857143	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2857143	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	2857	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	703225	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1529516	USD
CY2018	us-gaap	Prior Period Reclassification Adjustment PriorPeriodReclassificationAdjustment	300000	USD
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1693498	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2017	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	4649996	USD
CY2018	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	3857106	USD
CY2017	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	46861	USD
CY2018	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	72236	USD
CY2017	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	5685038	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	44612	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	586512	USD
CY2018Q4	us-gaap	Purchase Obligation PurchaseObligation	2522704	USD
CY2018Q4	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	0	USD
CY2018Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	1257326	USD
CY2018Q4	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	1265378	USD
CY2018Q4	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	0	USD
CY2017	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2374031	USD
CY2018	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4372578	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5786635	USD
CY2017	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2018	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	18723952	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	100000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1959	USD
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	18730	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	131353	USD
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	81725	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-58165260	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-98218070	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-98200000	USD
CY2018	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	8522461	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	1157252	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	2431063	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	19971554	USD
CY2017	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2017	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	46861	USD
CY2018	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	72236	USD
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1502593	USD
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	207002	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	27859608	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	20907748	USD
CY2017	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	344794	shares
CY2018	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18754799	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34773613	shares
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18410005	shares
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34773613	shares
CY2018	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;text-align:justify;text-indent:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company maintains a portion of its cash and cash equivalent balances in the form of a money market account with a financial institution that management believes to be creditworthy. The Company has no financial instruments with off‑balance sheet risk of loss.</font></div></div>
CY2018	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Business</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#ff0000;"></font><font style="font-family:inherit;font-size:10pt;">Cerecor Inc. (the "Company" or “Cerecor”) is a fully integrated biopharmaceutical company with commercial operations and research and development capabilities. The Company is building a robust pipeline of innovative therapies in pediatric healthcare, neurology, and orphan rare diseases. The Company's neurology pipeline is led by CERC-301, which is currently in a Phase I safety study for Neurogenic Orthostatic Hypotension ("nOH"). The Company is also developing </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> other neurological clinical and preclinical stage compounds. The Company's pediatric orphan rare disease pipeline is led by CERC-801, CERC-802 and CERC-803. All </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> of these compounds are preclinical therapies for inherited metabolic disorders known as Congenital Disorders of Glycosylation ("CDGs") by means of substrate replacement therapy. The U.S. Food and Drug Administration ("FDA") has granted Rare Pediatric Disease designation ("RPDD") and Orphan Drug Designation ("ODD") to all </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> compounds. Under the FDA’s Rare Pediatric Disease Priority Review Voucher ("PRV") program, upon the approval of a new drug application ("NDA") for the treatment of a rare pediatric disease, the sponsor of such application would be eligible for a PRV that can be used to obtain priority review for a subsequent new drug application or biologics license application. The PRV may be sold or transferred an unlimited number of times. The Company plans to leverage the 505(b)(2) NDA pathway for all </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> compounds to accelerate development and approval. The Company is also in the process of developing </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> other preclinical pediatric orphan rare disease compound, CERC-913. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also has a diverse portfolio of marketed products. Our marketed products are led by our prescribed dietary supplements and prescribed drugs. Our prescribed dietary supplements include Poly-Vi-Flor and Tri-Vi-Flor which are prescription vitamin and fluoride supplements used in infants and children to treat or prevent deficiency of essential vitamins and fluoride. The Company also markets a number of prescription drugs that treat a range of pediatric diseases, disorders and conditions. Cerecor's prescription drugs include Millipred®, Ulesfia®, Karbinal™ ER, AcipHex® Sprinkle™ and Cefaclor for Oral Suspension. Finally, the Company has </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> marketed medical device, Flexichamber™. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#ff0000;"></font><font style="font-family:inherit;font-size:10pt;">Cerecor was incorporated in 2011, commenced operations in the second quarter of 2011 and completed an initial public offering in October 2015. In August 2017, the Company sold its worldwide rights to CERC-501 to Janssen Pharmaceuticals, Inc. (“Janssen”) in exchange for initial gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$25 million</font><font style="font-family:inherit;font-size:10pt;">, of which </font><font style="font-family:inherit;font-size:10pt;">$3.75 million</font><font style="font-family:inherit;font-size:10pt;"> was deposited into a </font><font style="font-family:inherit;font-size:10pt;">twelve</font><font style="font-family:inherit;font-size:10pt;">-month escrow to secure indemnification obligations to Janssen. The Company collected the full amount of the escrow in August of 2018. Additionally, there is a potential future </font><font style="font-family:inherit;font-size:10pt;">$20 million</font><font style="font-family:inherit;font-size:10pt;"> regulatory milestone payment to the Company. The terms of the agreement provide that Janssen will assume ongoing clinical trials and be responsible for any new development and commercialization of CERC-501. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 17, 2017, the Company acquired TRx Pharmaceuticals, LLC (“TRx”) and its wholly-owned subsidiaries (see "TRx Acquisition" in Note 4 below for a description of the transaction).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 16, 2018, Cerecor acquired all rights to Avadel Pharmaceuticals PLC’s (“Avadel”) marketed pediatric products (the “Acquired Products”) for the assumption of certain of Avadel's financial obligations (see "Avadel Pediatric Products Acquisition" in Note 4 below for a description of the transaction).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 25, 2018, the Company acquired Ichorion Therapeutics, Inc., a privately-held biopharmaceutical company focused on developing treatments and increasing awareness of inherited metabolic disorders known as CDGs (see "Ichorion Asset Acquisition" in Note 4 below for a description of the transaction).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company applies a disciplined decision-making methodology as it evaluates the optimal allocation of the Company's resources between investing in the Company's current commercial product line, the Company's development portfolio and acquisitions or in-licensing of new assets in order to meet its cash flow needs. For the year ended December 31, 2018, Cerecor generated a net loss of </font><font style="font-family:inherit;font-size:10pt;">$40.1 million</font><font style="font-family:inherit;font-size:10pt;"> and negative cash flow from operations of </font><font style="font-family:inherit;font-size:10pt;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;">. As of December 31, 2018, Cerecor had an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$98.2 million</font><font style="font-family:inherit;font-size:10pt;"> and a balance of </font><font style="font-family:inherit;font-size:10pt;">$10.6 million</font><font style="font-family:inherit;font-size:10pt;"> in cash and cash equivalents. During the third quarter of 2018, the Company entered into a securities purchase agreement with Armistice Capital Master Fund Ltd. ("Armistice"), pursuant to which the Company sold </font><font style="font-family:inherit;font-size:10pt;">1,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock that generated net proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;"> (see "Armistice Private Placements" in Note 13 below for a description of the transaction). During the fourth quarter of 2018, Armistice exercised warrants for convertible preferred stock that generated net proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$5.7 million</font><font style="font-family:inherit;font-size:10pt;"> (see "December 2018 Armistice Private Placement" in Note 13 below for a description of the transaction). Additionally, during the first quarter of 2019, the Company closed on an underwritten public offering of common stock for </font><font style="font-family:inherit;font-size:10pt;">1,818,182</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock of the Company, at a price to the public of </font><font style="font-family:inherit;font-size:10pt;">$5.50</font><font style="font-family:inherit;font-size:10pt;"> per share ("public price"). Armistice participated in the offering by purchasing </font><font style="font-family:inherit;font-size:10pt;">363,637</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock of the Company from the underwriter at the public price. The net proceeds of the offering was approximately </font><font style="font-family:inherit;font-size:10pt;">$9.0 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;"></font><font style="font-family:inherit;font-size:10pt;">The Company plans to use cash and the anticipated positive net cash flows from the Company's existing product sales to offset costs related to its pediatric rare disease programs, neurology clinical programs, business development, costs associated with its organizational infrastructure and debt principal and interest payments. Cerecor expects to continue to incur significant expenses and operating losses for the immediate future as it continues to invest in the Company's pipeline assets. Our ability to achieve and maintain profitability in the future is dependent on, among other things, the development, regulatory approval and commercialization of our new product candidates and achieving a level of revenues from our existing product sales adequate to support our cost structure, which includes significant investment in our pipeline assets. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company believes it will require additional financing to continue to execute its clinical development strategy and/or fund future operations. The Company plans to meet its capital requirements through operating cash flows from product sales and some combination of equity or debt financings, collaborations, out-licensing arrangements, strategic alliances, federal and private grants, marketing, distribution or licensing arrangements or the sale of current or future assets. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible or suspend or curtail planned programs. If the Company raises additional funds through collaborations, strategic alliances or licensing arrangements with third parties, the Company may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our plan to aggressively develop our pipeline, including our recently acquired pediatric rare disease preclinical programs, will require substantial cash inflows in excess of what the Company expects our current commercial operations to generate. </font><font style="font-family:inherit;font-size:10pt;color:#ff0000;"> </font><font style="font-family:inherit;font-size:10pt;">The Company expects that our existing cash and cash equivalents, together with anticipated revenue, will enable us to fund our operating expenses, capital expenditure requirements, and other non-operating cash payments such as fixed quarterly payments on our outstanding debt balances through at least March 2020.</font></div></div>
CY2018	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassification</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During 2018, the Company concluded that going forward it would net amounts due to distributors against open receivable balances. The Company has reclassified </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> from accrued expenses and other current liabilities to accounts receivable, net in the December 31, 2017 balance sheet to conform with current period presentation. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During 2018, the Company concluded that going forward it would include amortization expense within its own standalone line in operating expenses in the Company's consolidated statements of operations. The Company has reclassified </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> from sales and marketing expenses in the December 31, 2017 statements of operations to conform with current period presentation.</font></div></div>
CY2018	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;text-indent:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to but not limited to, revenue recognition, cost of product sales, stock-based compensation, fair value measurements (including those relating to contingent consideration), cash flows used in management's going concern assessment, income taxes, goodwill and other intangible assets, and clinical trial accruals. The Company bases its estimates on historical experience and other market‑specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>

Files In Submission

Name	View Source	Status
0001628280-19-003078-index-headers.html	Edgar Link	pending
0001628280-19-003078-index.html	Edgar Link	pending
0001628280-19-003078.txt	Edgar Link	pending
0001628280-19-003078-xbrl.zip	Edgar Link	pending
cerc-20181231.xml	Edgar Link	completed
cerc-20181231.xsd	Edgar Link	pending
cerc-20181231_cal.xml	Edgar Link	unprocessable
cerc-20181231_def.xml	Edgar Link	unprocessable
cerc-20181231_lab.xml	Edgar Link	unprocessable
cerc-20181231_pre.xml	Edgar Link	unprocessable
cerc10-k20181231.htm	Edgar Link	pending
cerc800seriescharta01.jpg	Edgar Link	pending
cercex-211.htm	Edgar Link	pending
cercex-231.htm	Edgar Link	pending
cercex-311.htm	Edgar Link	pending
cercex-312.htm	Edgar Link	pending
cercex-321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pipelineassetchartfinala01.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
rdmilestonesfinala01.jpg	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVTX
Avalo Therapeutics, Inc. Stock $avtx

2019 Q1 Form 10-K Financial Statement

#000162828019003078 Filed on March 18, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVTX Avalo Therapeutics, Inc. Stock $avtx

2019 Q1 Form 10-K Financial Statement

#000162828019003078 Filed on March 18, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVTX
Avalo Therapeutics, Inc. Stock $avtx